The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy
- PMID: 33304783
- PMCID: PMC7714989
- DOI: 10.1016/j.apsb.2020.04.004
The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy
Abstract
Macrophages have a leading position in the tumor microenvironment (TME) which paves the way to carcinogenesis. Initially, monocytes and macrophages are recruited to the sites where the tumor develops. Under the guidance of different microenvironmental signals, macrophages would polarize into two functional phenotypes, named as classically activated macrophages (M1) and alternatively activated macrophages (M2). Contrary to the anti-tumor effect of M1, M2 exerts anti-inflammatory and tumorigenic characters. In progressive tumor, M2 tumor-associated macrophages (TAMs) are in the majority, being vital regulators reacting upon TME. This review elaborates on the role of TAMs in tumor progression. Furthermore, prospective macrophage-focused therapeutic strategies, including drugs not only in clinical trials but also at primary research stages, are summarized followed by a discussion about their clinical application values. Nanoparticulate systems with efficient drug delivery and improved antitumor effect are also summed up in this article.
Keywords: Combined therapy; Extracellular vesicles; Immunotherapy; Nano-drug; Targeted drug delivery; Tumor microenvironment; Tumor treatment; Tumor-associated macrophages.
© 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
Figures
Similar articles
-
The role of tumor-associated macrophage in breast cancer biology.Histol Histopathol. 2018 Feb;33(2):133-145. doi: 10.14670/HH-11-916. Epub 2017 Jul 6. Histol Histopathol. 2018. PMID: 28681373 Review.
-
Effect and Molecular Mechanisms of Traditional Chinese Medicine on Tumor Targeting Tumor-Associated Macrophages.Drug Des Devel Ther. 2020 Feb 28;14:907-919. doi: 10.2147/DDDT.S223646. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 32184560 Free PMC article. Review.
-
Targeting tumor-associated macrophages in the tumor microenvironment.Oncol Lett. 2020 Nov;20(5):234. doi: 10.3892/ol.2020.12097. Epub 2020 Sep 14. Oncol Lett. 2020. PMID: 32968456 Free PMC article. Review.
-
Tumor-associated macrophages as major players in the tumor microenvironment.Cancers (Basel). 2014 Aug 13;6(3):1670-90. doi: 10.3390/cancers6031670. Cancers (Basel). 2014. PMID: 25125485 Free PMC article. Review.
-
A narrative review of tumor-associated macrophages in lung cancer: regulation of macrophage polarization and therapeutic implications.Transl Lung Cancer Res. 2021 Apr;10(4):1889-1916. doi: 10.21037/tlcr-20-1241. Transl Lung Cancer Res. 2021. PMID: 34012800 Free PMC article. Review.
Cited by
-
Engineering customized nanovaccines for enhanced cancer immunotherapy.Bioact Mater. 2024 Mar 10;36:330-357. doi: 10.1016/j.bioactmat.2024.02.028. eCollection 2024 Jun. Bioact Mater. 2024. PMID: 38496036 Free PMC article. Review.
-
Exosome-mediated communication between gastric cancer cells and macrophages: implications for tumor microenvironment.Front Immunol. 2024 Feb 22;15:1327281. doi: 10.3389/fimmu.2024.1327281. eCollection 2024. Front Immunol. 2024. PMID: 38455041 Free PMC article. Review.
-
Immune landscape and response to oncolytic virus-based immunotherapy.Front Med. 2024 Mar 8. doi: 10.1007/s11684-023-1048-0. Online ahead of print. Front Med. 2024. PMID: 38453818 Review.
-
Nifuroxazide suppresses PD-L1 expression and enhances the efficacy of radiotherapy in hepatocellular carcinoma.Elife. 2024 Mar 5;12:RP90911. doi: 10.7554/eLife.90911. Elife. 2024. PMID: 38441416 Free PMC article.
-
Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance.NPJ Precis Oncol. 2024 Feb 10;8(1):31. doi: 10.1038/s41698-024-00522-z. NPJ Precis Oncol. 2024. PMID: 38341519 Free PMC article. Review.
References
-
- Chen D.S., Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1–10. - PubMed
-
- Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991–998. - PubMed
-
- Quesada J.R.R.J., Manning J.T., Hersh E.M., Gutterman J.U. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med. 1984;310:15–18. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
